Last reviewed 2026-04-23 · How we verify

Humalog® Mix25

Humalog® Mix25 is a premixed insulin formulation combining rapid-acting insulin lispro with intermediate-acting insulin isophane to provide both immediate and sustained blood glucose control.

Humalog® Mix25 is a premixed insulin formulation combining rapid-acting insulin lispro with intermediate-acting insulin isophane to provide both immediate and sustained blood glucose control. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.

At a glance

Mechanism of action

This combination insulin product delivers 25% rapid-acting insulin lispro (which begins working within 15 minutes) and 75% NPH insulin (intermediate-acting, peaking at 4-8 hours). The dual-component formulation allows for a single injection that addresses both postprandial (after-meal) glucose spikes and basal glucose control, simplifying the insulin regimen for patients with type 1 or type 2 diabetes.

Approved indications

• Type 1 diabetes mellitus
• Type 2 diabetes mellitus

Common side effects

• Hypoglycemia
• Injection site reactions
• Weight gain
• Lipodystrophy

Key clinical trials

• A Trial Investigating the Pharmacodynamics of BC Combo THDB0207 Compared With Humalog® Mix25 and Simultaneous Injections of Humalog® and Lantus® in Healthy Chinese Volunteers (PHASE1)
• A Trial Investigating the Dose Linearity and Safety of BC Combo THDB0207 in Subjects With Type 2 Diabetes (PHASE1)
• Efficacy and Safety of Insulin Lispro Biphasic 25 Compared to Humalog® Mix 25 in Type 2 Diabetes Mellitus Patients (PHASE3)
• A Study to Compare Pharmacokinetics and Pharmacodynamics of Insulin Lispro Mix 25 to Humalog® Mix 25 in Healthy Subjects (NA)
• A Trial to Investigate the Dose-linearity of BioChaperone® Combo 75/25 and the Safety at Three Different Doses in Subjects With Type 2 Diabetes (PHASE1)
• A Trial to Compare Post Prandial Blood Glucose Control of BioChaperone® Combo With Humalog® Mix25 and With Simultaneous Injections of Humalog® and Lantus® in Subjects With Type 2 Diabetes (PHASE1)
• A Trial to Assess the Efficacy and Safety of BioChaperone Combo and Humalog Mix 25 in Subjects With Type 1 Diabetes (PHASE1)
• A Trial to Compare the Pharmacodynamic and Pharmacokinetic Properties of Biochaperone® Combo With Humalog® Mix25 and With Simultaneous Injections of Humalog® and Lantus® in Subjects With Type 2 Diabetes (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.